A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV-2 main protease.
J. D. Baker, R. L. Uhrich, G. C. Kraemer, J. E. Love, B. C. Kraemer
This paper identifies hepatitis C antivirals as inhibitors of SARS-CoV-2 main protease through a drug repurposing screen of ~6,070 drugs.
PLOS ONE · Feb 1, 2021Peer-reviewedMicrobiology